fgf2  (R&D Systems)

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet:

Article Snippet: Mouse FGF basic/FGF2/bFGF DuoSet ELISA , R&D Systems , DY3139-05.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Catecholamine ELISA, Clinical Proteomics, Sandwich ELISA, Dehydrogenase Assay, Activity Assay, Software

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet: (A) Reactome pathway analysis of placental Sod3 f/f and Sod3 −/− dams. (B) Prl mRNA expression levels of 100 ng/mL recombinant fibroblast growth factor (FGF)1-, FGF2-, or FGF4-stimulated mouse primary pituitary cells with or without 10 μM FGF receptor (FGFR) inhibitors. BGJ398: FGFR1/2/3 inhibitor, PD16686: FGFR1 inhibitor, H3B-6527: FGFR4 inhibitor. N = 5; three technical replicates for each group; ** p < 0.01 vs. FGF1-control, †† p < 0.01 vs. FGF2-control, and ‡‡ p < 0.01 vs. FGF4-control. (C) Prl mRNA expression levels in recombinant FGF1-, FGF2-, or FGF4-stimulated primary pituitary cells from placental Sod3 f/f and Sod3 −/− dams on day 10 after delivery. (D) Phosphorylation levels of FGFR-induced signaling molecules in recombinant FGF1-, FGF2-, or FGF4-stimulated primary pituitary cells from placental Sod3 f/f and Sod3 −/− dams. N = 3 in each group; three biological and technical replicates for each group.

Article Snippet: Recombinant Mouse FGF2 Protein , Fujifilm Wako , 062–05181.

Techniques: Expressing, Recombinant, Control

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet: (A) Gene expression levels of FGFRs and FGFs of the pituitary gland in sedentary or trained, WT or KO dams. (B) FGFR2 and FGF1 protein expression levels in the pituitary gland from sedentary or trained, WT or KO dams. (C–E) Plasma levels of FGF1 (C), FGF2 (D), and FGF4 (E) in sedentary or trained, WT or KO dams. (F and H) Total 5-mC (F) and 5-hmC (H) of pituitary tissues in sedentary or trained, WT or KO dams. (G and I) Relative DNA methylation levels (G) and 5-hmC abundance (I) at the promoter of Fgfr/Fgf genes in the pituitary gland from sedentary or trained, WT or KO dams. (J) Gene expression levels of Tet and Idh of the pituitary gland in sedentary or trained, WT or KO dams. (K–M) Levels of α-ketoglutarate (αKG) (K) and enzymatic activity of IDH (L) and TET (M) in the pituitary glands of sedentary or trained, WT or KO dams. N = 5 in each group; three technical replicates for each group. For (B), three biological replicates for each group. * p < 0.05 and ** p < 0.01.

Article Snippet: Recombinant Mouse FGF2 Protein , Fujifilm Wako , 062–05181.

Techniques: Expressing, DNA Methylation Assay, Activity Assay

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet:

Article Snippet: Recombinant Mouse FGF2 Protein , Fujifilm Wako , 062–05181.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Catecholamine ELISA, Sandwich ELISA, Dehydrogenase Assay, Activity Assay, Software

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet: (A) Reactome pathway analysis of placental Sod3 f/f and Sod3 −/− dams. (B) Prl mRNA expression levels of 100 ng/mL recombinant fibroblast growth factor (FGF)1-, FGF2-, or FGF4-stimulated mouse primary pituitary cells with or without 10 μM FGF receptor (FGFR) inhibitors. BGJ398: FGFR1/2/3 inhibitor, PD16686: FGFR1 inhibitor, H3B-6527: FGFR4 inhibitor. N = 5; three technical replicates for each group; ** p < 0.01 vs. FGF1-control, †† p < 0.01 vs. FGF2-control, and ‡‡ p < 0.01 vs. FGF4-control. (C) Prl mRNA expression levels in recombinant FGF1-, FGF2-, or FGF4-stimulated primary pituitary cells from placental Sod3 f/f and Sod3 −/− dams on day 10 after delivery. (D) Phosphorylation levels of FGFR-induced signaling molecules in recombinant FGF1-, FGF2-, or FGF4-stimulated primary pituitary cells from placental Sod3 f/f and Sod3 −/− dams. N = 3 in each group; three biological and technical replicates for each group.

Article Snippet: Serum, plasma, and pituitary tissue levels of SOD3 (OKCD01107, Aviva System Biology), prolactin (ab100736, abcam), oxytocin (292–84401, Fujifilm Wako), estradiol (KGE014, R&D Systems), progesterone (CSB-E05104m, Cusabio), corticosterone (ab108821, abcam), dopamine (BA E–5300R, ImmuSmol), placental lactogen (LS-F28728–1, LifeSpan BioSciences), FGF1 (DY4686–05, R&D Systems), FGF2 (DY3139–05, R&D Systems), and FGF4 (ELM-FGF4–1, Ray Biotech) were determined using ELISA according to the manufacturer’s instructions.

Techniques: Expressing, Recombinant, Control

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet: (A) Gene expression levels of FGFRs and FGFs of the pituitary gland in sedentary or trained, WT or KO dams. (B) FGFR2 and FGF1 protein expression levels in the pituitary gland from sedentary or trained, WT or KO dams. (C–E) Plasma levels of FGF1 (C), FGF2 (D), and FGF4 (E) in sedentary or trained, WT or KO dams. (F and H) Total 5-mC (F) and 5-hmC (H) of pituitary tissues in sedentary or trained, WT or KO dams. (G and I) Relative DNA methylation levels (G) and 5-hmC abundance (I) at the promoter of Fgfr/Fgf genes in the pituitary gland from sedentary or trained, WT or KO dams. (J) Gene expression levels of Tet and Idh of the pituitary gland in sedentary or trained, WT or KO dams. (K–M) Levels of α-ketoglutarate (αKG) (K) and enzymatic activity of IDH (L) and TET (M) in the pituitary glands of sedentary or trained, WT or KO dams. N = 5 in each group; three technical replicates for each group. For (B), three biological replicates for each group. * p < 0.05 and ** p < 0.01.

Article Snippet: Serum, plasma, and pituitary tissue levels of SOD3 (OKCD01107, Aviva System Biology), prolactin (ab100736, abcam), oxytocin (292–84401, Fujifilm Wako), estradiol (KGE014, R&D Systems), progesterone (CSB-E05104m, Cusabio), corticosterone (ab108821, abcam), dopamine (BA E–5300R, ImmuSmol), placental lactogen (LS-F28728–1, LifeSpan BioSciences), FGF1 (DY4686–05, R&D Systems), FGF2 (DY3139–05, R&D Systems), and FGF4 (ELM-FGF4–1, Ray Biotech) were determined using ELISA according to the manufacturer’s instructions.

Techniques: Expressing, DNA Methylation Assay, Activity Assay

Journal: Cell reports

Article Title: Placenta-derived SOD3 deletion impairs maternal behavior via alterations in FGF/FGFR-prolactin signaling axis

doi: 10.1016/j.celrep.2024.114789

Figure Lengend Snippet:

Article Snippet: Serum, plasma, and pituitary tissue levels of SOD3 (OKCD01107, Aviva System Biology), prolactin (ab100736, abcam), oxytocin (292–84401, Fujifilm Wako), estradiol (KGE014, R&D Systems), progesterone (CSB-E05104m, Cusabio), corticosterone (ab108821, abcam), dopamine (BA E–5300R, ImmuSmol), placental lactogen (LS-F28728–1, LifeSpan BioSciences), FGF1 (DY4686–05, R&D Systems), FGF2 (DY3139–05, R&D Systems), and FGF4 (ELM-FGF4–1, Ray Biotech) were determined using ELISA according to the manufacturer’s instructions.

Techniques: Recombinant, Enzyme-linked Immunosorbent Assay, Catecholamine ELISA, Sandwich ELISA, Dehydrogenase Assay, Activity Assay, Software

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: Development and characterization of a novel injectable thyroid extracellular matrix hydrogel for enhanced thyroid tissue engineering applications

doi: 10.3389/fbioe.2024.1481295

Figure Lengend Snippet: Structural, Mechanical, and Growth Factor Characterization of Thyroid Extracellular Matrix (TEM) Hydrogels. (A) SEM images of type I collagen hydrogel, 10 mg/mL TEM hydrogel, and 20 mg/mL TEM hydrogel. (B) Elastic modulus of native thyroid tissue, type I collagen hydrogel, 10 mg/mL TEM hydrogel, and 20 mg/mL TEM hydrogel. (C) Toughness of native thyroid tissue, type I collagen hydrogel, 10 mg/mL TEM hydrogel, and 20 mg/mL TEM hydrogel. (D) Concentrations of growth factors (VEGF, TGF-β, HGF, FGF, EGF, and PDGF) in native thyroid tissue, 10 mg/mL TEM hydrogel, and 20 mg/mL TEM hydrogel. All data represent means ± SD. (n = 6; ** p < .01 vs. native thyroid, and p < .01 vs. 10 mg/mL TEM hydrogel).

Article Snippet: Specific ELISA kits were used to detect the content of growth factors, including VEGF (R&D Systems, RRV00), TGF-β (R&D Systems, RTB100B), HGF (R&D Systems, MHG00), FGF (R&D Systems, MFB00), EGF (R&D Systems, DY3214), and PDGF (R&D Systems, MBB00).

Techniques: